Next Article in Journal
Peripheral Delivery of Neural Precursor Cells Ameliorates Parkinson’s Disease-Associated Pathology
Next Article in Special Issue
Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation
Previous Article in Journal
The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer
Previous Article in Special Issue
Natural Sulfur-Containing Compounds: An Alternative Therapeutic Strategy against Liver Fibrosis
Open AccessReview

Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression

by Aline Gottlieb 1 and Ali Canbay 2,*
1
Department of Physiology, Johns Hopkins University, Baltimore, MD 21224, USA
2
Department of Medicine, Ruhr University Bochum, University Hospital Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany
*
Author to whom correspondence should be addressed.
Cells 2019, 8(11), 1358; https://doi.org/10.3390/cells8111358
Received: 2 October 2019 / Revised: 27 October 2019 / Accepted: 28 October 2019 / Published: 30 October 2019
Non-alcoholic fatty liver disease (NAFLD) is a complex disease, affecting not just the liver, but also all other organs in the body. Despite an increasing amount of people worldwide developing NAFLD and having it progress to non-alcoholic steatohepatitis (NASH) and potentially cirrhosis, there is still no approved therapy. Therefore, huge efforts are being made to find and develop a successful treatment. One of the special interests is understanding the liver–gut axis and especially the role of bile acids in the progression of NAFLD. Farnesoid X receptor (FXR)-agonists have been approved und used in other liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), and have shown signs of being able to decrease inflammation and potentially steatosis. This review will mainly focus on targets/ligands that play an important role in bile acid metabolism and give an overview of ongoing clinical as well as pre-clinical trials. With the complexity of the issue, we did not aim at giving a complete review, rather highlighting important targets and potential treatments that could be approved for NAFLD/NASH treatment within the next few years. View Full-Text
Keywords: bile acids; bile acid metabolism; NAFLD/NASH therapy; lipid metabolism; gut-liver axis; UDCA; OCA bile acids; bile acid metabolism; NAFLD/NASH therapy; lipid metabolism; gut-liver axis; UDCA; OCA
Show Figures

Figure 1

MDPI and ACS Style

Gottlieb, A.; Canbay, A. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression. Cells 2019, 8, 1358.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop